• Tempus AI disclosed a Heart Rhythm publication validating its FDA-cleared ECG-AF software for predicting 12-month atrial fibrillation risk.
• Results have already been presented via the peer-reviewed publication, not flagged for a future conference readout.
• The multi-center study found the model met performance expectations across different clinical settings, supporting its use as a decision-support tool.
• Management framed the product as a shift toward earlier detection to reduce downstream complications, strengthening its cardiovascular device portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606110830BIZWIRE_USPR_____20260611_BW397471) on June 11, 2026, and is solely responsible for the information contained therein.